Eosinophilia future or investigational therapies

Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases
If the severely elevated eosinophilia count is felt to be the cause of the patient’s symptoms, there are a number of treatments that specifically lower eosinophil counts
Anti-IL5 antibody Mepolizumab is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids. ^[1]

References

↑ Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. NEJM 2008; 358:1215-1228